[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hearing-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hearing-impairment":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,43,66,127,156,183,218,238,267,293,316],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100053950","hears-maryland-extending-capacity-for-affordable-accessible-hearing-care-through-older-adult-peer-mentorship-100053950",false,"NCT07699146","HEARS Maryland: Extending Capacity for Affordable, Accessible Hearing Care Through Older Adult Peer Mentorship","HEARS MD","Inclusion Criteria:\n\n* Age 60 years or older\n* English-speaking\n* Aural-oral verbal communication as primary communication modality\n* Post-lingual hearing loss (Audiometric pure tone averages \\[0.5-2kHz\\] in better ear \\>25 dB)\n\nExclusion Criteria:\n\n* Current self-reported use of hearing aid or amplification device\n* Medical contraindication to use hearing aids (e.g. draining ears)",true,"ALL","60 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to assess the effectiveness of a Community Health Worker (CHW) delivered hearing loss intervention program (HEARS) for older adults in Maryland in collaboration with community organizations.",[27,28,29,30],"Hearing Loss","Hearing Impairment","Age Related Hearing Loss","Age-related Hearing Impairment","NOT_YET_RECRUITING","2026-07-07",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":21},"2026-11",{"date":39,"type":21},"2029-12",{"name":41,"class":42},"Johns Hopkins University","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100567110","clinical-evaluation-of-frequency-allocation-for-bimodal-ci-users-100567110","NCT06663917","Clinical Evaluation of Frequency Allocation for Bimodal CI Users","Inclusion Criteria:\n\n1. Age 18 or older\n2. Regular usage of a cochlear implant device with at least 18 active electrodes, and compliance with programming\u002Fappointments\n3. Received a cochlear implant at least 6 months ago and use a hearing aid in the contralateral ear\n4. Pure tone average (.5, 1, and 2kHz) between 30 and 70 dB (decibel) hearing level in the contralateral (hearing aid) ear\n5. Standard FAT use for all programs prior to study participation\n6. No known anatomical abnormalities in either ear\n7. English speaking\n8. No known cognitive impairments\n9. At least 25% of subjects should use the Cochlear EA32 electrode\n\nExclusion Criteria:\n\n1. Under age 18\n2. Non-English speaking. Participants that are Non-English speaking are excluded from this study due to the use of speech testing materials that are validated in the English language. Additionally, study team members are not equipped to appropriately score speech testing materials validated in other languages.\n3. Cognitively impaired\n4. Non-consistent device usage\n5. Greater than 70 dB hearing level pure tone average in the contralateral ear\n6. Normal hearing or mild hearing loss in the contralateral ear\n7. Non-standard FAT programs\n8. Use of any frequency transposition programming in hearing aid.","18 Years",{"count":51,"type":21},13,[24],"This study will examine experienced, bimodal cochlear implant (CI) patients who receive an alternative frequency allocation table (FAT) to determine how it improves sound quality, device satisfaction, and speech perception abilities with respect to the standard default FAT. The goal of this study is to investigate how improving place-pitch mismatch in bimodal CI users affects 1) sound quality, 2) satisfaction, and 3) speech perception.",[28],"RECRUITING","2026-06-23",{"date":58,"type":35},"2026-06-26",{"date":60,"type":35},"2024-10-06",{"date":62,"type":21},"2027-10-06",{"name":64,"class":42},"NYU Langone Health",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":81,"conditions":82,"keywords":107,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":65},"100616316","phase-1-a-treatment-for-a-form-of-age-related-central-auditory-processing-disorder-consisting-of-clemastine-fumarate-plus-engineered-sound-100616316","NCT07304024","A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound","A Double-Blinded, Placebo-Controlled, Randomized, Phase 1\u002F2a Clinical Study to Test the Safety and Efficacy of a Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound","CAPD-LOOT","Inclusion Criteria:\n\n* Male or female between 45 and 65 years old (middle aged) at the screening\u002Fenrollment visit (Visit 1).\n* Written informed consent obtained from the subject and ability for the subject to comply with the requirements of the study.\n* Documentation of no more than a mild high-frequency hearing sensitivity loss and normal middle-ear function will be obtained using standard audiometric equipment with measurements done by an audiologist; Specifically, testing will show:\n\n  * bilateral hearing thresholds \\\u003C 20 dB HL at audiometric frequencies from 250 Hz to 4000 Hz inclusively, with no air-bone gaps \\> 10 dB.\n  * symmetrical hearing thresholds between the ears through 8000 Hz, defined as \\\u003C20 dB difference at any single audiometric frequency or \\\u003C 15 dB difference at 2 or more contiguous frequencies.\n  * normal (Type A) tympanograms bilaterally.\n* No cognitive deficit shown upon screening with the Montreal Cognitive Assessment (MOCA) test (Nasreddine et al. 2005).\n* Distortion product otoacoustic emission (DPOAE) showing no more than 20 dB hearing loss at audiometric frequencies from 250 Hz to 4000 Hz.\n* Subjects failing the hearing in noise test at 15 degrees. Failing is defined as SNR being 12 dB below from what is found in normal hearing subjects without central hearing loss.\n\nExclusion Criteria:\n\n* Any subjects who do not fall under the criteria defined above.\n* Any of the following conditions which are listed as contraindications or warnings for use of the clinical trial drug (from labeling):\n\n  * Known sensitivity to clemastine fumarate or other antihistamines of similar composition\n  * Pregnancy or nursing mother as determined objectively with a urine pregnancy test\n  * Lower respiratory tract disease including asthma, or breathing difficulties such as emphysema or chronic bronchitis\n  * Glaucoma or increased intraocular pressure\n  * Stenosing peptic ulcers or pyloroduodenal obstruction\n  * Trouble urinating due to an enlarged prostate gland. Mild urinary issues (Stage 1 Benign Prostatic Hyperplasia) will not be considered an automatic exclusion but it must be emphasized to patients with this diagnosis that difficulty urinating is a possible side effect that may compound their BPH symptoms.\n  * Significant cardiovascular disease, chronic hypertension or hypotension\n  * Hyperthyroidism\n  * Alcoholism- as defined by consuming on average 3+ drinks per day for women or 4+ drinks per day for men or previous diagnosis of alcohol use disorder by a clinician as defined by DSM V criteria.\n  * Patients with a history of seizures will be excluded.\n  * Patients with evidence of suicidal ideation\u002Fbehavior as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS).\n* We will generally exclude subjects with significant or uncontrolled medical disorders (e.g., hepatic, hematologic, renal, gastrointestinal, neurological, psychiatric disorders). We will define these patients as those who fall outside of normal ranges for a physical examination of vital signs, a 12-lead EKG, and a safety clinical laboratory assessment including complete blood count (CBC) and comprehensive metabolic panel (CMP). Exclusion with these tests will specifically focus on identifying the following disorders based on the listed criteria:\n* Leukopenia as defined as a CBC white blood cell count \\\u003C 4000\u002Ful\n* Anemia as defined by a CBC Hemoglobin \\\u003C9.0 g\u002FdL or \\\u003C10.0 g\u002FdL (Grade 2+ CTCAE)\n* Lymphopenia as defined by CBC Absolute lymphocyte count \\\u003C1000\u002FµL.\n* Neutropenia as defined by CBC ANC \\\u003C1500\u002FµL (solid tumors), ANC \\\u003C1000\u002FµL (hematologic malignancies). In the case of participants with African, Middle Eastern or West Indian descent a clinician's judgement will be considered to assess the possibility of benign ethnic neutropenia which is not an exclusion criteria.\n* Thrombocytopenia as defined by CBC Platelet count \\\u003C75000\u002FµL\n* Hepatic Impairment based on CMP: Total bilirubin \\>1.5× ULN, AST\u002FALT \\>3× ULN (or \\>5× ULN if liver metastases), Alkaline phosphatase \\>3× ULN.\n* Hepatic Impairment based on CMP: Serum creatinine \\>2.0 mg\u002FdL (alternative threshold).\n* Metabolic abnormalities based on CMP: Albumin \\\u003C3.0 g\u002FdL\n* Taking medications that would contraindicate taking the clinical trial drug; Specifically, (from labeling):\n\n  * Monoamine oxidase inhibitor therapy\n  * CNS depressants (sedatives, tranquilizers, hypnotics)\n* A history of significant otologic disorder such as repetitive ear infections or Meniere's disease\n* A history of significant neurologic disorder, or current neurodegenerative diseases such as multiple sclerosis, which could present a confound and impact the electrophysiological outcome measures.\n* A history of traumatic brain or closed head injury because this can cause symptoms of central auditory processing problems unrelated to aging and demyelination.\n* English as a second language (non-native English speakers), which is known to negatively impact scores on speech recognition testing.\n* Presence of any other condition or abnormality that in the opinion of the Investigator or his co-PIs would compromise the safety of the patient or the quality of the data.","45 Years","65 Years",{"count":77,"type":21},344,[79,80],"PHASE1","PHASE2","The goal of this clinical trial is to determine the efficacy of Clemastine Fumarate in the presence of engineered sound to treat age-related central auditory processing disorder (CAPD). This disorder impacts 800M patients worldwide, including \\~1\u002F3 people over 40 years of age and \\~1\u002F2 people over 65, resulting in an inability to hear in noisy environments.\n\nThe primary hypothesis this study aims to test is: engineered sound, driving localized neural circuit activity, will enable Clemastine Fumarate to mature Oligodendrocyte cells and thus remyelinate these activated neural circuits. This Localized Oligodendrocyte Optimization Therapy (LOOT) was highly effective in preclinical animal studies so this clinical trial aims to answer if this therapy will translate to humans.\n\nThe study is an adaptive design intended to compare the efficacy of the drug in the presence or absence of the engineered sound for improving hearing in noise ability. Trial participants will be tested for hearing thresholds and ability to isolate a sound signal from background noise. If they meet the inclusion criteria, they will be enrolled into one of the four arms of the study and undergo the proposed one-month treatment (drug and sound or respective placebos). After the treatment period, trial participants will be tested again for hearing thresholds and their ability to isolate s sound source of interest from background noise. The hypothesis to be tested in this clinical trial is that the one-month treatment will significantly improve the participant's ability to isolate a sound source of interest from background noise.\n\nThe design has four arms, drug+sound, placebo+sound, drug+white noise, and placebo+white noise. Based on our preclinical data, control arms are all expected to show identical results, thus our adaptive design includes interim analyses to allow for dropping of two of the three placebo arms should the preclinical results be replicated as anticipated.\n\nWe will also monitor each participant's general health during the duration of the clinical trial, which will be done by performing a number of blood tests, an EKG and a general physical before and after the one-month treatment period. We expect no significant changes since participants will take the drug for the one-month period at dosages already demonstrated safe in several Phase II studies of multiple sclerosis. Similarly, the engineered sound will be listened to for one hour per day during this month at sound intensities well below threshold that might cause noise-induced hearing damage.",[83,84,85,86,87,88,89,90,91,92,28,27,93,94,95,96,97,98,99,100,101,102,103,104,105,106],"Central Auditory Processing Disorder","Hearing Impaired (Partially)","Hearing","Hearing Abnormality","Hearing Disability","Hearing Disorder","Hearing Disorders","Hearing Impairment, Sensorineural","Hearing Handicap","Hearing Impaired","Central Auditory Disease","Noise Exposure","Noise Induced Hearing Loss","Noise-Induced Hearing Loss","Sound Perception","Myelin Degeneration","Myelinopathy","Myelin Integrity","Remyelination","Hidden Hearing Loss","Cocktail Party Skill","Cocktail Party Syndrome","CAPD","Age Problem",[108,102,109,110,111,112,113,114,115,116,105,117],"clemastine fumarate","Cocktail Party","Engineered Sound","Sound Therapy","central auditory processing disorder","Hearing in noise","oligodendrocyte","Localized Oligodendrocyte Optimization Therapy","LOOT","Age-Related Hearing Loss","2026-04-28",{"date":120,"type":35},"2026-04-30",{"date":122,"type":35},"2025-03-31",{"date":124,"type":21},"2028-07",{"name":126,"class":42},"University of Colorado, Denver",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":16,"sex":17,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100623094","speech-evoked-auditory-potentials-multisite-pediatric-evaluation-100623094","NCT07392164","Speech-Evoked Auditory Potentials: Multisite Pediatric Evaluation","SEFR","Inclusion Criteria:\n\n1. Infants (3 to 24 months of age) with normal hearing who have passed their audiological diagnostic evaluation\n2. Infants (3 to 24 months of age) identified with hearing loss at their audiological diagnostic evaluation, whose parents have chosen spoken language as their form of communication, and who have been prescribed and fitted with a hearing aid(s).\n\nExclusion Criteria:\n\nParticipants who have abnormal middle ear measure results or occluding ear wax will be excluded.","3 Months","24 Months",{"count":137,"type":21},20,[24],"The goal of this study is to evaluate the sensitivity of a newly-developed prototype device in its ability to measure brain responses to speech sounds in an infant population. The main research questions are: 1) Is the prototype sensitive to brain response differences from infants with hearing loss with and without hearing aids? and 2) How do the measured brain responses from infants with hearing loss compare to infants with normal hearing who are the same age? Participants will have their brain responses measured using the prototype in response to average-level non-sense speech sounds across 1 to 2 sessions in a \"no-hearing aids\" condition. Participants with hearing loss who are already fit with hearing aids will additionally undergo a \"with hearing aids\" recording condition.",[28],[85,142,143,144,145],"Hearing impairment","Hearing aids","Evoked potentials","Pediatrics","2026-01-29",{"date":148,"type":35},"2026-02-06",{"date":150,"type":21},"2026-03",{"date":152,"type":21},"2026-12",{"name":154,"class":42},"Susan Scollie",3,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":163,"targetDuration":165,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":65},"100568416","cabp2-patient-registry-and-natural-history-study-100568416","NCT06680934","CABP2 Patient Registry and Natural History Study","Patient Registry for Individuals With CABP2-Associated Hearing Loss","Inclusion Criteria:\n\n* A molecular genetic diagnosis involving biallelic variants in CAPB2 and audiometry\n\nExclusion Criteria:\n\n* Patients with evidence of non-CABP2 molecular genetic diagnoses",{"count":164,"type":21},100,"25 Years","OBSERVATIONAL","This registry is designed to collect comprehensive information about the molecular genetic diagnoses and clinical information of individuals with CABP2-associated hearing impairment to support a natural history study.",[169,28],"CABP2-related Auditory Synaptopathy",[171,172,173],"CABP2 patient registry","Patient registry","DFNB93","2026-01-23",{"date":176,"type":35},"2026-01-27",{"date":178,"type":35},"2024-08-16",{"date":180,"type":21},"2049-08-16",{"name":182,"class":42},"University Medical Center Goettingen",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":200,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":65},"100599211","comparative-analysis-of-hearing-outcomes-robotic-vs-manual-insertion-of-cochlear-implants-100599211","NCT07081542","Comparative Analysis of Hearing Outcomes: Robotic vs. Manual Insertion of Cochlear Implants","Inclusion Criteria:\n\n* Cochlear implant candidates \\>18 years of age\n* LFPTA (125Hz, 250Hz, 500Hz) \\\u003C80dB\n\nExclusion Criteria:\n\n* Pediatric patients (below the age of 18)\n* LFPTA (125Hz, 250Hz, 500Hz) \\>80dB\n* Revision cases\n* Severe comorbidities that contraindicate surgery.\n* Preexisting cochlear anomalies.\n* Do not speak English or Spanish","80 Years",{"count":191,"type":21},32,[24],"This research study is evaluating two different methods of cochlear implant (CI) insertion - robotic-assisted insertion and manual insertion - to better understand how they affect hearing outcomes. Participants in this study will be randomly assigned to receive their cochlear implant using one of these two techniques. Both methods are performed in a standard operating room by qualified surgeons, and both are considered safe and approved for use.\n\nThe main goal is to compare how well participants hear one year after surgery based on the insertion method used. The study will also look at things like surgical time, inner ear health, and how the hearing nerve responds. All participants will receive the same type of cochlear implant device and follow-up care.\n\nThis study may help guide future surgical techniques and improve outcomes for individuals receiving cochlear implants.",[195,196,197,89,198,199,28],"Sensorineural Hearing Loss","Bilateral Hearing Loss","Cochlear Implantation","Hearing Disorders and Deafness","Inner Ear Disorders",[201,202,203,204,205,206,207,208],"Cochlear Implant","Robotic Cochlear Implant Insertion","Hearing Performance","Speech Perception","Electrocochleography","Hearing Rehabilitation","Postoperative Hearing Outcomes","Minimally Invasive ENT Surgery","2025-12-30",{"date":211,"type":35},"2026-01-02",{"date":213,"type":21},"2026-01-01",{"date":215,"type":21},"2027-01-31",{"name":217,"class":42},"AdventHealth",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":224,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":65},"100501140","evaluating-a-noise-reduction-algorithm-with-cochlear-implant-users-100501140","NCT05805384","Evaluating a Noise Reduction Algorithm With Cochlear Implant Users","Inclusion Criteria:\n\n* At least 12 years of age.\n* Be post-lingually deafened cochlear implant recipients with at least 6 months experience regardless of manufacturer.\n* The PI must also deem the child to be developmentally able to complete the experiments.\n\nExclusion Criteria:\n\n• Anyone who is not a cochlear implant user or is aged under 12 years.","12 Years",{"count":226,"type":21},60,[24],"In this study, a noise reduction algorithm will be implemented in various listening situations to evaluate its effectiveness in improving speech understanding for cochlear implant users ages 12 and older.",[28],"2025-12-15",{"date":232,"type":35},"2025-12-17",{"date":234,"type":35},"2023-03-01",{"date":236,"type":21},"2027-03-01",{"name":64,"class":42},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":247,"conditions":248,"keywords":255,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100605333","sentio-systematic-evaluation-100605333","NCT07161154","Sentio Systematic Evaluation","Sentio Systematic Evaluation - SENSE","SENSE","Inclusion Criteria:\n\n* Subject who is scheduled for or have undergone Sentio implantation in clinical practice.\n* Subject who has consented to participation or are covered by consent waiver.\n\nExclusion Criteria:\n\n* Subjects enrolled in other clinical investigations leading to their Sentio implantation and subsequent follow-up deviating substantially from clinical practice",{"count":164,"type":21},"The study is designed as an international, multi-center, single-armed, non-interventional\u002Fobservational study including subjects who has received or are planned to receive the Sentio system as part of normal clinical practice.",[249,250,251,252,27,253,254],"Hearing Loss, Bilateral or Unilateral","Hearing Loss, Conductive","Hearing Loss, Mixed Conductive-Sensorineural","Single Sided Deafness","Hearing-Impairment","Hearing Aid",[256],"Active transcutaneous bone conduction hearing system","2025-09-03",{"date":259,"type":35},"2025-09-08",{"date":261,"type":21},"2025-09",{"date":263,"type":21},"2035-12",{"name":265,"class":266},"Oticon Medical","INDUSTRY",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":16,"sex":17,"minAge":273,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":276,"briefSummary":277,"conditions":278,"keywords":279,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":292},"100504370","improving-early-intervention-in-hearing-impaired-children-using-functional-near-infrared-spectroscopy-fnirs-100504370","NCT05847426","Improving Early Intervention in Hearing Impaired Children Using Functional Near-Infrared Spectroscopy (fNIRS)","The above eligibility applies to the participating audiologists who are in the experimental and control arms of the study\n\nAudiologist Inclusion Criteria:\n\n* Is a qualified audiologist who meets the criteria for membership of Audiology Australia.\n* Has at least 1 year of experience in paediatric diagnostic, hearing aid or cochlear implant audiology service provision in Australia.\n* Provides a signed and dated informed consent form.\n\nAudiologist Exclusion criteria (only for a specific infant test result):\n\n* Is the managing audiologist for the infant who's results are being provided.\n\nInfants are also recruited into the study to have an fNIRS assessment performed. They do not participate further after the fNIRS test.\n\nInfant Inclusion criteria:\n\n* Between the ages of 1 and 24 months at the time of fNIRS testing.\n* Has permanent hearing loss in one or both ears as determined by audiological diagnostic testing.\n* Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf.\n\nInfant Exclusion Criteria:\n\n* There are no exclusion criteria other than not meeting the inclusion criteria.","24 Years",{"count":275,"type":21},40,[24],"The goal of this clinical trial is to find out whether hearing test results using functional near-infrared spectroscopy (fNIRS) will help to fast-track early intervention for infants born with a hearing loss. fNIRS is a method of imaging brain activity using light. The main questions are:\n\n1. Can audiologists make more confident decisions about the optimal interventions at different critical points in the hearing care pathway when they are given additional fNIRS information compared to when they have standard audiology test results alone?\n2. Is the experience of their infant having an fNIRS test acceptable and comfortable for the parents or care givers?",[28],[280,281,282],"Infants","Early intervention","functional near-infrared spectroscopy","2025-08-14",{"date":285,"type":35},"2025-08-19",{"date":287,"type":35},"2023-05-02",{"date":289,"type":21},"2028-04-28",{"name":291,"class":42},"The Bionics Institute of Australia",5,{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":300,"targetDuration":165,"studyType":166,"phases":4,"briefSummary":301,"conditions":302,"keywords":304,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":65},"100511946","otoferlin-patient-registry-and-natural-history-study-100511946","NCT05946057","Otoferlin Patient Registry and Natural History Study","Patient Registry for Individuals With Otoferlin-Associated Hearing Loss","Inclusion Criteria:\n\n* A molecular genetic diagnosis involving biallelic variants in otoferlin (OTOF) and audiometry\n\nExclusion Criteria:\n\n* Patients with evidence of non-OTOF molecular genetic diagnoses",{"count":164,"type":21},"This registry is designed to collect comprehensive information about the molecular genetic diagnoses of individuals with otoferlin-associated hearing impairment and clinical information to support a natural history study.",[303,28],"Otoferlin-related Auditory Synaptopathy",[305,306],"Otoferlin patient registry","Natural history study","2025-05-21",{"date":309,"type":35},"2025-05-28",{"date":311,"type":35},"2023-02-21",{"date":313,"type":21},"2048-02-21",{"name":315,"class":42},"Tobias Moser",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":331,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":65},"100559083","effect-of-psycho-educational-interventions-in-communication-partners-of-older-adults-with-hearing-impairment-100559083","NCT06559514","Effect of Psycho-Educational Interventions in Communication Partners of Older Adults With Hearing Impairment","The Effectiveness of Group-based Multi-Component Psycho-Educational Interventions (GMC-PEIs) on Burden, Depression, Coping and Quality of Life in Communication Partners of Older Adults With Hearing Impairment","Inclusion Criteria:\n\n* being18 or older\n* living with older adults with hearing impairment\n* they were indicated that as primary communication partner\n* no known hearing loss\n* having normal cognitive function\n* articulate in the Mandarin Chinese language\n* signing a consent form to participate\n\nExclusion Criteria:\n\n* severe psychiatric disorders\n* the communication partner who is hired as a caregiver",{"count":324,"type":21},92,[24],"Hearing impairment is a critical health problem throughout the world. In addition, having an impact on the biopsychosocial functioning of older adults, it places enormous stress and burden on communication partners who interact with older adults with hearing impairment every day. These communication partners generally have restrictions to their social lives and an increased communication burden, as well as symptoms of depression and adopting maladaptive coping and poorer quality of life. Therefore, group-based multi-component psycho-educational interventions are recommended. The purposes of this study are to examine the effects of group-based multi-component psycho-educational interventions (GMC-PEIs) on burden, depression, coping and quality of life in communication partners of older adults with hearing impairment. The single-blind, randomized control trial will include communication partners of older adults with hearing impairment. Participants will be randomized to either intervention groups or control groups.",[328,28,329,330],"Older Adults","Nursing","Communication Partners",[332,333,334,335,336,337,338,339,340],"group-based multi-component interventions","psychoeducation","hearing impairment","older adults","communication partners","burden","depression","coping","quality of life","2024-08-15",{"date":343,"type":35},"2024-08-19",{"date":345,"type":21},"2024-09-01",{"date":347,"type":21},"2026-07-31",{"name":349,"class":42},"National Taiwan University Hospital"]